The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.The treatment, called ivonescimab, has become a symbol of China’s rise in drug development. Cancer, Lung Cancer, Drugs (Pharmaceuticals), Summit Therapeutics Inc, Clinical Trials, Food and Drug Administration, Regulation and Deregulation of Industry, Biotechnology and Bioengineering, China, United States International Relations Read More
F.D.A. Rejects Closely Watched Lung Cancer Drug From China


